Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
568
Recruiting Now
568
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT06961214 Phase 3
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Ob...
Condition
Pulmonary Disease, Chronic Obstructive
Enrollment
961 pts
Location
United States, Argentina, Australia
Sponsor
GlaxoSmithKline
NCT07683000 Phase 3
Recruiting
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed A...
Condition
HIV-1-infection
Enrollment
590 pts
Location
United States
Sponsor
Gilead Sciences
NCT07871864 Phase 3
Recruiting
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagno...
Condition
Osteosarcoma
Enrollment
530 pts
Location
Denmark, Finland, France
Sponsor
Gustave Roussy, Cancer Campus,
NCT05232916 Phase 3
Recruiting
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (...
Condition
Breast Cancer
Enrollment
2,250 pts
Location
United States, Belgium, France
Sponsor
Greenwich LifeSciences, Inc.
NCT06526533 Phase 3
Recruiting
RECOMMEND Platform Trial
Condition
Extracorporeal Membrane Oxygenation Complication
Enrollment
600 pts
Location
Australia
Sponsor
Australian and New Zealand Int
NCT03669315 Phase 3
Recruiting
Modulating Inhibitory Control Networks in Gambling Disorder With Theta Burst Sti...
Condition
Gambling Disorder
Enrollment
40 pts
Location
Italy
Sponsor
CNS Onlus
NCT04304625 Phase 3
Recruiting
TRAnexamic Acid for Preventing Blood Loss Following a Cesarean Delivery in Women...
Condition
Postpartum Hemorrhage
Enrollment
1,380 pts
Location
France
Sponsor
University Hospital, Bordeaux
NCT03594760 Phase 3
Recruiting
PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Pro...
Condition
Prostate Cancer
Enrollment
1,000 pts
Location
Canada
Sponsor
Centre hospitalier de l'Univer
NCT05006482 Phase 3
Recruiting
Geriatric Evaluation and Management With Survivorship Health Education for Older...
Condition
Lymphoma
Enrollment
668 pts
Location
United States
Sponsor
University of Rochester
NCT06145893 Phase 3
Recruiting
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Dis...
Condition
Behçet's Disease
Enrollment
162 pts
Location
China
Sponsor
Ganzhou Hemay Pharmaceutical C
NCT05377047 Phase 3
Recruiting
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
Condition
Breast Cancer Stage IV
Enrollment
345 pts
Location
Ireland, Israel, Italy
Sponsor
Vastra Gotaland Region
NCT02568878 Phase 3
Recruiting
Creatine for Depressed Male and Female Methamphetamine Users
Condition
Depression
Enrollment
29 pts
Location
United States
Sponsor
Montana State University
NCT07280585 Phase 3
Recruiting
STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease
Condition
Polycystic Kidney, Autosomal Dominant
Enrollment
420 pts
Location
Austria, Germany, Netherlands
Sponsor
University of Cologne
NCT06998524 Phase 3
Recruiting
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Typ...
Condition
Von Willebrand Disease, Type 3
Enrollment
75 pts
Location
United States, Belgium, Canada
Sponsor
Hoffmann-La Roche
NCT05899010 Phase 3
Recruiting
MIcronized PROgesterone in Frozen Embryo Transfer Cycles
Condition
Infertility
Enrollment
1,020 pts
Location
Spain
Sponsor
Fundación Santiago Dexeus Font
NCT05382338 Phase 3
Recruiting
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hear...
Condition
Childhood Medulloblastoma
Enrollment
225 pts
Location
United States, Canada
Sponsor
Children's Oncology Group
NCT06578078 Phase 3
Recruiting
A Clinical Trial to Define the Best Strategy for the Management of Heart Failure...
Condition
Heart Failure
Enrollment
94 pts
Location
Spain
Sponsor
Fundación para la Investigació
NCT07671885 Phase 3
Recruiting
Evaluating the Response-Guided Therapy With Neoadjuvant Endocrine Therapy to Opt...
Condition
Breast Cancer
Enrollment
950 pts
Location
Japan
Sponsor
Tokyo Women's Medical Universi
NCT07215585 Phase 3
Recruiting
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Condition
Large B-cell Lymphoma
Enrollment
420 pts
Location
Australia, Belgium, Brazil
Sponsor
AstraZeneca
NCT07320625 Phase 3
Recruiting
Efficacy of Montelukast on STEMl Patients
Condition
Myocardial Infarction (MI)
Enrollment
512 pts
Location
China
Sponsor
Shanghai Zhongshan Hospital
NCT06542549 Phase 3
Recruiting
Efficacy and Safety of AK104 Combined With Chemotherapy for Neoadjuvant Treatmen...
Condition
Advanced Ovarian Cancer
Enrollment
100 pts
Location
China
Sponsor
Anhui Provincial Hospital
NCT07531043 Phase 3
Recruiting
Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adul...
Condition
Ocular Hyperemia
Enrollment
230 pts
Location
United States
Sponsor
Alcon Research
NCT05358535 Phase 3
Recruiting
Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)
Condition
Anesthesia
Enrollment
200 pts
Location
United States
Sponsor
University of Texas Southweste
NCT03895359 Phase 3
Recruiting
Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiat...
Condition
Hepatocellular Carcinoma
Enrollment
128 pts
Location
Canada
Sponsor
London Health Sciences Centre
NCT07247188 Phase 3
Recruiting
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children...
Condition
Sickle Cell Disease
Enrollment
100 pts
Location
United States, Dominican Republic
Sponsor
Sanofi
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology